Cargando…

Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination

BACKGROUND: Brain inflammation plays a central role in numerous brain pathologies, including multiple sclerosis (MS). Microglial cells and astrocytes are the effector cells of neuroinflammation. They can be activated also by agents such as interferon-γ (IFN-γ) and lipopolysaccharide (LPS). Peroxisom...

Descripción completa

Detalles Bibliográficos
Autores principales: Defaux, Antoinette, Zurich, Marie-Gabrielle, Braissant, Olivier, Honegger, Paul, Monnet-Tschudi, Florianne
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687435/
https://www.ncbi.nlm.nih.gov/pubmed/19422681
http://dx.doi.org/10.1186/1742-2094-6-15
_version_ 1782167530944593920
author Defaux, Antoinette
Zurich, Marie-Gabrielle
Braissant, Olivier
Honegger, Paul
Monnet-Tschudi, Florianne
author_facet Defaux, Antoinette
Zurich, Marie-Gabrielle
Braissant, Olivier
Honegger, Paul
Monnet-Tschudi, Florianne
author_sort Defaux, Antoinette
collection PubMed
description BACKGROUND: Brain inflammation plays a central role in numerous brain pathologies, including multiple sclerosis (MS). Microglial cells and astrocytes are the effector cells of neuroinflammation. They can be activated also by agents such as interferon-γ (IFN-γ) and lipopolysaccharide (LPS). Peroxisome proliferator-associated receptor (PPAR) pathways are involved in the control of the inflammatory processes, and PPAR-β seems to play an important role in the regulation of central inflammation. In addition, PPAR-β agonists were shown to have trophic effects on oligodendrocytes in vitro, and to confer partial protection in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. In the present work, a three-dimensional brain cell culture system was used as in vitro model to study antibody-induced demyelination and inflammatory responses. GW 501516, a specific PPAR-β agonist, was examined for its capacity to protect from antibody-mediated demyelination and to prevent inflammatory responses induced by IFN-γ and LPS. METHODS: Aggregating brain cells cultures were prepared from embryonal rat brain, and used to study the inflammatory responses triggered by IFN-γ and LPS and by antibody-mediated demyelination induced by antibodies directed against myelin-oligodendrocyte glycoprotein (MOG). The effects of GW 501516 on cellular responses were characterized by the quantification of the mRNA expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), inducible NO synthase (i-NOS), PPAR-β, PPAR-γ, glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), and high molecular weight neurofilament protein (NF-H). GFAP expression was also examined by immunocytochemistry, and microglial cells were visualized by isolectin B4 (IB4) and ED1 labeling. RESULTS: GW 501516 decreased the IFN-γ-induced up-regulation of TNF-α and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-β agonist. However, it increased IL-6 m-RNA expression. In demyelinating cultures, reactivity of both microglial cells and astrocytes was observed, while the expression of the inflammatory cytokines and iNOS remained unaffected. Furthermore, GW 501516 did not protect against the demyelination-induced changes in gene expression. CONCLUSION: Although GW 501516 showed anti-inflammatory activity, it did not protect against antibody-mediated demyelination. This suggests that the protective effects of PPAR-β agonists observed in vivo can be attributed to their anti-inflammatory properties rather than to a direct protective or trophic effect on oligodendrocytes.
format Text
id pubmed-2687435
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26874352009-05-28 Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination Defaux, Antoinette Zurich, Marie-Gabrielle Braissant, Olivier Honegger, Paul Monnet-Tschudi, Florianne J Neuroinflammation Research BACKGROUND: Brain inflammation plays a central role in numerous brain pathologies, including multiple sclerosis (MS). Microglial cells and astrocytes are the effector cells of neuroinflammation. They can be activated also by agents such as interferon-γ (IFN-γ) and lipopolysaccharide (LPS). Peroxisome proliferator-associated receptor (PPAR) pathways are involved in the control of the inflammatory processes, and PPAR-β seems to play an important role in the regulation of central inflammation. In addition, PPAR-β agonists were shown to have trophic effects on oligodendrocytes in vitro, and to confer partial protection in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. In the present work, a three-dimensional brain cell culture system was used as in vitro model to study antibody-induced demyelination and inflammatory responses. GW 501516, a specific PPAR-β agonist, was examined for its capacity to protect from antibody-mediated demyelination and to prevent inflammatory responses induced by IFN-γ and LPS. METHODS: Aggregating brain cells cultures were prepared from embryonal rat brain, and used to study the inflammatory responses triggered by IFN-γ and LPS and by antibody-mediated demyelination induced by antibodies directed against myelin-oligodendrocyte glycoprotein (MOG). The effects of GW 501516 on cellular responses were characterized by the quantification of the mRNA expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), inducible NO synthase (i-NOS), PPAR-β, PPAR-γ, glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), and high molecular weight neurofilament protein (NF-H). GFAP expression was also examined by immunocytochemistry, and microglial cells were visualized by isolectin B4 (IB4) and ED1 labeling. RESULTS: GW 501516 decreased the IFN-γ-induced up-regulation of TNF-α and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-β agonist. However, it increased IL-6 m-RNA expression. In demyelinating cultures, reactivity of both microglial cells and astrocytes was observed, while the expression of the inflammatory cytokines and iNOS remained unaffected. Furthermore, GW 501516 did not protect against the demyelination-induced changes in gene expression. CONCLUSION: Although GW 501516 showed anti-inflammatory activity, it did not protect against antibody-mediated demyelination. This suggests that the protective effects of PPAR-β agonists observed in vivo can be attributed to their anti-inflammatory properties rather than to a direct protective or trophic effect on oligodendrocytes. BioMed Central 2009-05-07 /pmc/articles/PMC2687435/ /pubmed/19422681 http://dx.doi.org/10.1186/1742-2094-6-15 Text en Copyright © 2009 Defaux et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Defaux, Antoinette
Zurich, Marie-Gabrielle
Braissant, Olivier
Honegger, Paul
Monnet-Tschudi, Florianne
Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title_full Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title_fullStr Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title_full_unstemmed Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title_short Effects of the PPAR-β agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination
title_sort effects of the ppar-β agonist gw501516 in an in vitro model of brain inflammation and antibody-induced demyelination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687435/
https://www.ncbi.nlm.nih.gov/pubmed/19422681
http://dx.doi.org/10.1186/1742-2094-6-15
work_keys_str_mv AT defauxantoinette effectsofthepparbagonistgw501516inaninvitromodelofbraininflammationandantibodyinduceddemyelination
AT zurichmariegabrielle effectsofthepparbagonistgw501516inaninvitromodelofbraininflammationandantibodyinduceddemyelination
AT braissantolivier effectsofthepparbagonistgw501516inaninvitromodelofbraininflammationandantibodyinduceddemyelination
AT honeggerpaul effectsofthepparbagonistgw501516inaninvitromodelofbraininflammationandantibodyinduceddemyelination
AT monnettschudiflorianne effectsofthepparbagonistgw501516inaninvitromodelofbraininflammationandantibodyinduceddemyelination